Provided by Tiger Trade Technology Pte. Ltd.

Glaukos

172.18
+10.596.55%
Post-market: 173.551.37+0.80%19:30 EDT
Volume:1.49M
Turnover:255.15M
Market Cap:10.16B
PE:-53.05
High:174.48
Open:161.00
Low:159.59
Close:161.59
52wk High:191.62
52wk Low:73.16
Shares:58.98M
Float Shares:56.44M
Volume Ratio:1.86
T/O Rate:2.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2456
EPS(LYR):-3.2819
ROE:-25.98%
ROA:-5.18%
PB:14.88
PE(LYR):-52.46

Loading ...

Glaukos Chief Development Officer Tomas Navratil Disposes of $251,194 in Common Shares

Reuters
·
2 hours ago

Glaukos Says Late-Stage Eye Disease Treatment Shows Lasting Benefits After Single Dose

Reuters
·
4 hours ago

Glaukos Says Phase 3 Extension Study Shows Epioxa Epi-on Corneal Cross-Linking Benefits Durable Through Three Years in Keratoconus

Reuters
·
5 hours ago

Glaukos Corporation - no Serious Adverse Events or Discontinuations Reported in Three Years After Epioxa

THOMSON REUTERS
·
5 hours ago

Glaukos Corporation - Three-Year Follow-up Shows Durable Efficacy and Favorable Safety for Epioxa

THOMSON REUTERS
·
5 hours ago

Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus

THOMSON REUTERS
·
5 hours ago

Movement Alert|Glaukos Rises 6.57% in Regular Trading, 2026 Sales Guidance Materially Raised

Market Focus
·
Yesterday

Glaukos Schedules Third-Quarter 2026 Results Release, Conference Call

Reuters
·
Yesterday

What Glaukos Holders Were Betting On All Along

Simply Wall St.
·
Yesterday

Glaukos (GKOS) Could Be 17% Below Fair Value After Its Strong Share Price Run

Simply Wall St.
·
Oct 04

Glaukos Expands Real-World iDose TR Data: What Investors Should Watch

TIPRANKS
·
Oct 01

Glaukos Chief Development Officer Tomas Navratil Disposes of Common Shares Worth USD 245,456.09

Reuters
·
Sep 29

Glaukos partners with Stephen Curry for keratoconus awareness campaign

TIPRANKS
·
Sep 23

US Research Roundup-Boeing, Twilio, WP Carey

Reuters
·
Sep 22

Glaukos Chief Development Officer Tomas Navratil Sells 1,457 Common Shares Worth $242,953.44

Reuters
·
Sep 19

Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbbVie (ABBV)

TIPRANKS
·
Sep 04

Top Glaukos Executive Makes Bold Insider Move in High-Value Stock Sale

TIPRANKS
·
Sep 02

Glaukos Chief Development Officer Tomas Navratil Sells Common Shares Worth $2.49 Million

Reuters
·
Sep 02

Glaukos (GKOS) On The iDose TR Narrative And Why Valuation Still Draws Attention

Simply Wall St.
·
Aug 31

Glaukos (GKOS), Why Is The Story Getting Harder To Ignore?

Simply Wall St.
·
Aug 24